Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques

Journal of Virology

Volumn 80, Issue 19, 2006, Pages 9577-9585

  Simmons, Monika ^a   Porter, Kevin R ^a,b   Hayes, Curtis G ^a   Vaughn, David W ^c   Putnak, Robert ^c  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HYBRID PROTEIN; INACTIVATED VIRUS VACCINE; MALTOSE BINDING PROTEIN; PROTEIN SUBUNIT; RECOMBINANT PROTEIN; VIRUS DNA; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DENGUE VIRUS 2; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE GUN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RHESUS MONKEY; VACCINATION; VIREMIA; VIRUS GENE; VIRUS NEUTRALIZATION; VIRUS PLAQUE; VIRUS TYPING;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; IMMUNOLOGIC MEMORY; MACACA MULATTA; VACCINES, DNA; VERO CELLS; VIRAL PROTEINS; VIRAL VACCINES; VIREMIA;

ANIMALIA; DENGUE VIRUS TYPE 2; ESCHERICHIA COLI; MACACA MULATTA;

EID: 33748923173     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00284-06     Document Type: Article

References (31)

1. Barnett, S. W., S. Rajasekar, H. Legg, B. Doe, D. H. Fuller, J. R. Hayens, C. M. Walker, and K. S. Steimer. 1997. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15:869-873.
2. Bhamarapravati, N., and S. Yoksan. 1997. Live-attenuated tetravalent dengue vaccine, p. 367-377. In D. J. Gubler and G. Kuno (ed.), Dengue and dengue hemorrhagic fever. CAB International, Cambridge, United Kingdom.
3. Burton, D. R. 2002. Antibodies, viruses and vaccines. Nat. Rev. 2:706-713.
4. Chanock, R. M., J. E. Crowe, B. R. Murphy, and D. R. Burton. 1993. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases. Infect. Agents Dis. 2:118-131.
5. Chung, K. M., G. E. Nybakken, B. S. Thompson, M. J. Engle, A. Marri, D. H. Fremont, and M. S. Diamond. 2006. Antibodies against West Nile nonstructural protein NS1 prevent lethal infection through Fc γ receptor-dependent and -independent mechanisms. J. Virol. 80:1340-1351.
6. Endy, T. P., A. Nisalak, S. Chunsuttitwat, D. W. Vaughn, S. Green, F. A. Ennis, A. L. Rothman, and D. H. Library. 2004. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189:990-1000.
7. Fujinami, R. S., and M. B. Oldstone. 1979. Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature 279:529-530.
8. Gerhard, W. 2001. The role of the antibody response in influenza virus infection. Curr. Top. Microbiol. Immunol. 260:171-190.
9. Henchal, E. A., L. S. Henchal, and J. J. Schlesinger. 1988. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 69:2101-2107.
10. Hooks, J. J., W. Burns, K. Hayashi, S. Geis, and A. L. Notkins. 1976. Viral spread in the presence of neutralization antibody: mechanisms of persistence in foamy virus infections. Infect. Immun. 14:1172-1178.
11. Kanesa-Thasan, N., W. Sun, G. Kim-Ahn, S. Van Albert, R. Putnak, A. King, B. Raengsakulsrach, H. Christ-Schmidt, K. Gilson, J. Zahradnik, D. Vaughn, B. Innis, J. Saluzzo, and C. Hoke. 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19:3179-3188.
12. Kato, H., R. Kato, K. Fujihashi, and J. R. McGhee. 2001. Role of mucosal antibodies in viral infections. Curr. Top. Microbiol. Immunol. 260:201-228.
13. Kochel, T., D. M. Watts, A. S. Gozalo, D. F. Ewing, K. R. Porter, and K. L. Russell. 2005. Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J. Infect. Dis. 191:1000-1004.
14. Levine, B., J. M. Hardwick, B. D. Trapp, T. O. Crawford, R. C. Bollinger, and D. E. Griffin. 1991. Antibody-mediated clearance of alpha virus infection from neurons. Science 254:856-860.
15. Manzanec, M. B., C. L. Coudret, and D. R. Fletcher. 1995. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. 69:1339-1343.
16. McCullough, K. C., D. Parkinson, and J. R. Crowther. 1988. Opsonization-enhanced phagocytosis of foot-and-mouth disease virus. Immunology 65: 187-191.
17. Monath, T. P. 1986. Pathology of the flaviviruses, p. 375-440. In S. Schlesinger and M. J. Schlesinger (ed.), The Togaviridae and Flaviviridae. Plenum, New York, N.Y.
18. 17a. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
19. Pantaleo, G., J. F. Demarest, M. Vaccarezza, C. Graziosi, G. P. Bansal, S. Koenig, and A. S. Fauci. 1995. Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. Eur. J. Immunol. 25:226-231.
20. Putnak, R., D. Barvir, J. Burrous, D. Dubois, V. Dandrea, C. Hoke, J. Sadoff, and K. Eckels. 1996. Development of a purified, inactivated dengue 2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus macaques. J. Infect. Dis. 174:1176-1184.
21. Putnak, R., J. Fuller, L. Vanderzanden, B. Innis, and D. Vaughn. 2003. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am. J. Trop. Med. Hyg. 68:469-476.
22. Rodriguez-Carreno, M. P., M. S. Nelson, J. Botten, K. Smith-Nixon, M. J. Buchmeier, and J. L. Whitton. 2005. Evaluating the immunogenicity and protective efficacy of DNA vaccine encoding Lassa virus nucleoprotein. Virology 335:87-89.
23. Russell, P. K., A. Nisalak, P. Sukhavachana, and S. Vivona. 1967. A plaque reduction test for dengue virus neutralizing antibodies. J. Immunol. 99:285-290.
24. Sabchareon, A., J. Lang, P. Chanthavanich, S. Yoksan, R. Forrat, P. Attanath, C. Sirivichayakul, K. Pengsaa, C. Pojjaroen-Anant, W. Chokejindachai, A. Jagsudee, J. F. Saluzzo, and N. Bhamarapravati. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype, concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66:264-272.
25. Schlesinger, J. J., M. W. Brandriss, C. B. Cropp, and T. P. Monath. 1986. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 60:1153-1155.
26. Sedegah, M., T. R. Jones, M. Kaur, R. Hedstrom, P. Hobart, J. A. Tine, and S. L. Hoffman. 1998. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 95:7648-7653.
27. Simmons, M., W. M. Nelson, S. J. Wu, and C. G. Hayes. 1998. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg. 58:655-662.
28. Simmons, M., G. S. Murphy, T. Kochel, K. Raviprakash, and C. G. Hayes. 2001. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyg. 65:420-426.
29. Someya, K., K. Q. Xin, K. Matsuo, K. Okuda, N. Yamamoto, and M. Honda. 2004. A consecutive priming-boosting vaccination in mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J. Virol. 78:9842-9853.
30. Stephens, H. A., R. Klaythong, M. Sirikong, D. W. Vaughn, S. Green, S. Kalayanarooj, T. P. Endy, D. H. Library, A. Nisalak, B. L. Innis, A. L. Rothman, F. A. Ennis, and D. Chandanayingyong. 2002. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 60:309-318.
31. Vaughn, D. W., C. H. Hoke, S. Yoksan, R. LaChance, B. L. Innis, R. M. Rice, and N. Bhamarapravati. 1996. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14:329-336.